top of page
Publications
Our consultants bring over 40 years of combined experience across HEOR, HTA and statistics, and have authored peer-reviewed research in academic, government and industry settings
Selected Publications
The work below spans therapeutic areas and evidence types. Much of our client work is confidential, so this is a selection of what we can share publicly.
Publication | Year | Output Type | Therapeutic Area | Evimed Author |
|---|---|---|---|---|
Evidence from Europe on implementation, participation and performance of self-collection for cervical cancer screening | 2026 | Journal article | Oncology | Susie Huntington |
Estimating the potential health economic value of introducing universal opt-out testing for HIV in emergency departments in Italy | 2025 | Journal article | Infectious disease | Susie Huntington |
Estimating the number of people who could benefit from HIV pre-exposure prophylaxis (PrEP) in England and the unmet need | 2025 | Journal article | Infectious disease | Susie Huntington |
Development of a Partitioned Survival Model Template for Oncology Indications: A Flexible and Customizable Framework | 2025 | Conference abstract | Oncology | Chaitanyamayee Kalakota; Jiumei Gao; Necdet Gunsoy |
Worse outcomes in young women compared to men presenting with ST-elevation myocardial infarction: a 15-year statewide population-linkage cohort study | 2023 | Conference abstract | Cardiovascular | Robin Philip |
Outcomes of 46,770 patients with type 2 myocardial infarction: a statewide population-linkage study | 2023 | Conference abstract | Cardiovascular | Robin Philip |
An economic evaluation of two PCR-based respiratory panel assays for patients admitted to hospital with community-acquired pneumonia in the UK, France and Spain | 2023 | Journal article | Infectious disease | Susie Huntington |
Two self-sampling strategies for HPV primary cervical cancer screening compared with clinician-collected sampling: an economic evaluation | 2023 | Journal article | Oncology | Susie Huntington |
Page 1 of 1
Let's talk about your access challenge
Tell us the indication, the markets and the deadline. A senior consultant replies — there is no account manager in between.
bottom of page